The delegation from SensoDetect, including key figures like Dr. Mohamed Hussein Atwa Ahmed and Ahmad Alosta, has introduced an updated market strategy featuring two commercial models: Private School Screening Programs and SensoDetect-Owned Screening Centers. These models aim to provide standardized neuro-auditory screening to identify neurodevelopmental conditions early. CEO PA Hedin emphasized the growing interest in structured screening in the region and the importance of combining school programs with company-owned centers for accessibility and long-term presence. An ongoing autism study is on track, with future data expected to enhance screening workflows. Dr. Mohamed emphasized the alignment of the SensoDetect BERA method with current initiatives, while Mrs. Neven Ahmad highlighted the test's impact on families. Ahmad Alosta noted the openness of school networks to integrate screening into student health programs, and Maher Almajzoub stressed the importance of local coordination for sustained adoption. Further updates will follow as agreements are finalized.

SensoDetect AB has announced that it has received all license payments from its joint venture with Beijing Mind Exploration Medical Technology Co., Ltd. on time. The company reports significant progress in their collaboration, with the successful installation and activation of their AI software in Beijing. Early tests show that their BERA 4.2 system can now complete neurophysiological tests in under 5 minutes and 30 seconds, with AI calculations taking less than 10 seconds. This advancement improves the system's speed, efficiency, and reliability for clinical and research applications. CEO Per-Anders Hedin expressed satisfaction with the financial and technological developments, highlighting the potential of their technology to enhance clinical diagnostics. The company plans to proceed with further clinical validation, regulatory preparations, and production scaling. This follows a recent investment round aimed at supporting a large-scale launch in China. For further information, contact CEO PA Hedin.

SensoDetect AB has completed its initial investment round in its Chinese joint venture, Beijing Mind Exploration Medical Technology Co., Ltd. Two key investors, Mr. Lu Zhong and Mr. Lu Weihua, have joined the venture. Mr. Lu Zhong is a prominent figure in China's technology and investment sectors with significant experience, while Mr. Lu Weihua is a legal and investment expert with connections to a large investment consortium. Their involvement strengthens the joint venture's capital and positions it for the commercialization of SensoDetect's technologies in China. The company will now focus on clinical validation and market readiness.

SensoDetect Aktiebolag har meddelats att en aktieägares innehav har passerat vissa gränsvärden för aktier och röster, vilket företaget enligt Spotlight Stock Markets regler måste offentliggöra. Företagets största aktieägare, Thomas Holmgren, har avlidit och innan sin död överlät han 4,98 procent av sitt aktieinnehav i företaget till sina anhöriga. Före överlåtelsen ägde Holmgren 15,18 procent av kapitalet och rösterna i företaget. Efter överlåtelsen uppgår innehavet till 45,114,213 aktier, motsvarande 10,20 procent av kapitalet och rösterna i företaget. En uppdaterad lista över företagets tio största aktieägare kommer att publiceras på företagets webbplats. VD Per-Anders Hedin uttrycker sin tacksamhet för Holmgren, som var en betydande aktieägare och stödjare av företaget, och betonar hans inflytande och arv. Informationen offentliggjordes enligt lag den 14 oktober 2025. För ytterligare information kan VD PA Hedin kontaktas.

SensoDetect AB has announced new international collaborations to advance its clinical validation program for neuropsychiatric diagnostics. The company plans to launch initiatives with partners in the Middle East, Europe, and Asia to enhance its clinical reach and support its sales and marketing strategies. A significant part of this effort is an ongoing autism spectrum disorder study in Saudi Arabia, which is being bolstered with additional resources and partnerships. SensoDetect is also preparing data collection programs for ADHD research using advanced technology. Dr. Fatimah Saeed Alahmari has been appointed as a medical advisor to optimize the Saudi study and facilitate data collection. Her appointment underscores the company's commitment to the Middle East. CEO P-A Hedin emphasized the importance of these collaborations and announced future partnerships. Dr. Mohamed Atwa has moved to Sweden to work closely with the R&D team, and CEO Hedin will visit Dubai to strengthen regional relationships. These efforts aim to establish SensoDetect as a leader in neuropsychiatric diagnostic tools.

SensoDetect AB, a company specializing in tools for neurodevelopmental disorders, has appointed Dr. Fatimah Saeed Alahmari as its new Medical Advisor. Dr. Alahmari, a Developmental and Behavioural Paediatrician, brings over 20 years of experience and is currently involved in key healthcare roles in Saudi Arabia. Her appointment is part of SensoDetect's strategy to enhance its technology's clinical validation in the MENA region. Dr. Alahmari's connections and expertise will support large-scale data collection and integration of SensoDetect's solutions into clinical settings. She is committed to using technology to improve diagnostics for autism and ADHD. This move is expected to advance SensoDetect's clinical validation and regulatory approval processes.

Sensodetect AB has announced strategic initiatives to advance its clinical validation program and enhance its AI-driven diagnostic platform. The company is focusing on an autism spectrum disorder study in Saudi Arabia and launching broader data collection projects to improve its software. Dr. Atwa, Head of Clinical Research, has moved to Sweden to collaborate more closely with the R&D team, while CEO P-A Hedin plans to visit Dubai to engage with regional partners. Sensodetect is collecting neurophysiological data from diverse populations in China, the Middle East, and Europe to train advanced machine learning algorithms. This expanded dataset is crucial for developing precise diagnostic tools and strengthens the company's position for future regulatory submissions. Sensodetect aims to be a leader in medical technology, focusing on innovative solutions for neuropsychiatric diagnostics.

SensoDetect AB has announced a technological breakthrough that could allow the company to gain a significant share of the global neuropsychiatric diagnostics market. By using artificial intelligence on its Brainstem Evoked Response Audiometry (BERA) tests, SensoDetect has achieved diagnostic accuracy for ADHD that rivals more complex methods like MRI and EEG, but with better scalability and speed. The company is the first to apply AI to an Auditory Brainstem Response database, offering commercial benefits such as faster test times, cost efficiency, patient comfort, and scalability. CEO P-A Hedin highlighted the competitive advantage provided by their proprietary BERA database and the potential for faster commercial rollout and market leadership. The company plans to integrate this AI software into its global strategy to boost adoption rates and generate new revenue through IP licensing.

Under andra kvartalet 2025 tog SensoDetect flera viktiga steg framåt, inklusive att presentera sin neurodiagnostiska teknologi vid en internationell kongress, öppna ett nytt kontor nära Karolinska Institutet och lansera screening för ADHD och autism i Stockholm. Företaget gjorde också kliniska framsteg i sin autismstudie och lanserade ett AI-initiativ för att påskynda kommersialiseringen. Interimsresultat från en studie i Saudiarabien offentliggjordes. Finansiellt sett rapporterade moderbolaget en nettoomsättning på 102 KSEK för kvartalet och ett resultat efter finansiella poster på -2 507 KSEK. Likvida medel uppgick till 8 158 KSEK vid periodens slut, och soliditeten var 89%. För första halvåret 2025 var nettoomsättningen 222 KSEK och resultatet efter finansiella poster -4 455 KSEK. Efter kvartalets slut satte företaget som mål att ta 10% av den globala diagnostikmarknaden för ASD/ADHD. Planer för expansion i Kina presenterades, och ett JV-bolag i Kina vann en innovationstävling. VD PA Hedin uttryckte att SensoDetect står väl rustat för framtiden med en stark balansräkning, etablerade intäktsströmmar och en tydlig strategi för internationell expansion.

Sensodetect AB och deras joint venture-bolag Beijing Mental Exploration Medical Technology Co., Ltd. har vunnit första pris i "Jinying Cup" Innovation and Entrepreneurship Competition i Kina. Tävlingen organiseras av Tsinghua University och Jinxin Capital. Deras neurodiagnostiska plattform, "New ABR Technology", har potential på Kinas växande marknad för hjärnhälsoscreening. Vinsten ger dem tillgång till tillväxtkapital och resurser för marknadsetablering, samt kontakt med sjukhusnätverk. De får också skatteförmåner och upphandlingskontrakt värda betydande summor. SensoDetects VD, PA Hedin, uttrycker glädje över vinsten och förväntar sig snabbare godkännanden och ökad intäktsprognos för 2026.